Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TP-6076 · 1 trial · 1 indication
Pharmacokinetics
| Arm | Type | Description |
|---|---|---|
| BAL PK study | EXPERIMENTAL | Bronchoalveolar lavage procedure performed at either 2, 4, 8, or 24 hours after final dose of TP-6076 on Day 4 |
| Name | Type | Description |
|---|---|---|
| TP-6076 | DRUG | The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4). |
| Bronchoalveolar lavage | PROCEDURE | Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4. |
Inclusion Criteria: * The following inclusion criteria must be met for a subject to be eligible for inclusion in the study: 1. Status : Healthy subject 2. Gender : Male or female 3. Age : 18 to 50 years, inclusive, at screening 4. Body mass index (BMI) : 18.0 to 30.0 kg/m2, inclusive, at s...
TP-6076 is an investigational small molecule being studied in healthy subjects. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety and bronchopulmonary pharmacokinetics in healthy volunteers. The drug is not approved and remains under investigation.
TP-6076 is being developed by Innoviva, Inc., a company traded on the Nasdaq under the ticker INVA. The company is conducting clinical research on this investigational small molecule in healthy subjects.
TP-6076 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in healthy subjects. One Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
TP-6076 has one completed Phase 1 trial, NCT03691584, titled 'Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers.' This study enrolled 8 participants in the United Kingdom and evaluated the drug's safety and pharmacokinetics in healthy subjects.
TP-6076 is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development. The drug has completed a Phase 1 trial in healthy subjects, but it remains under investigation and has not been approved for any use.